Search

Search Constraints

You searched for: Author/Creator Kogner, Per

Search Results

1. Aberrant splicing in neuroblastoma generates RNA-fusion transcripts and provides vulnerability to spliceosome inhibitors. Issue 5 (8th February 2021)

2. Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project. (3rd August 2017)

3. Analysis of ALK, MYCN, and the ALK ligand ALKAL2 (FAM150B/AUGα) in neuroblastoma patient samples with chromosome arm 2p rearrangements. Issue 1 (2nd September 2019)

4. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Issue 4 (April 2017)

6. Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor‐stroma drug targeting. Issue 8 (5th July 2020)

8. Frequency and Prognostic Impact of ALK Amplifications and Mutations in the European Neuroblastoma Study Group (SIOPEN) High-Risk Neuroblastoma Trial (HR-NBL1). Issue 30 (20th October 2021)

9. Frequent detection of human cytomegalovirus in neuroblastoma: A novel therapeutic target?. Issue 10 (13th July 2013)